Virus and drug combo takes on tough cancers
NCT ID NCT07185243
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early study tests a new combination therapy for people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses a modified virus (hV01) designed to infect and kill cancer cells while boosting the immune system, plus an immunotherapy drug (tislelizumab) that helps the immune system attack the cancer. The trial will enroll 24 participants to check safety and see if the combination can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
a modified virus (hV01) that carries an immune-boosting protein, plus an immunotherapy drug (tislelizumab)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that haven't responded to standard therapies.
What could go wrong
This is a very early, small trial (24 people) focused mainly on safety. The combination may not shrink tumors or could cause serious side effects. Success is far from guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xiamen Humanity Hospital
RECRUITINGXiamen, Fujian, 361000, China